Biogen Inc. BDR | |
Stock Exchange | Brazilian Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
1.21 B |
Public Float |
- |
Biogen Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$23.21 |
Market Cap |
$45.42 B |
Shares Outstanding |
193.89 M |
Public Float |
196.38 M |
Biogen Inc. | |
Stock Exchange | Santiago Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
211.01 M |
Public Float |
210.43 M |
Biogen Inc. | |
Stock Exchange | SIX Swiss Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
201.44 M |
Public Float |
210.43 M |
Address |
225 Binney Street Cambridge Massachusetts 02142 United States |
Employees | - |
Website | http://www.biogen.com |
Updated | 07/08/2019 |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |